News | December 11, 2025
Bristol Myers Squibb unveils breakthrough Lymphoma data
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site marks the company’s first operation in the region
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Subscribe To Our Newsletter & Stay Updated
